Product Information
CALCIUM ACETATE 667 MG CAPSULE is a generic product labeled by Cipla USA Inc., priced at $0.1697 per EA under NDC 69097086283. Its NADAC has been published 525 times since Sep 14, 2016.
FDA first approved this application on Feb 7, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
667 mg/1
Manufacturer
Cipla USA Inc.NDC
69097086283
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CALCIUM ACETATEApproval Type
Generic (ANDA)
FDA Application
ANDA203135FDA Approved
2/7/2013
TE Code
AB
On Market Since
7/26/2016
Pharmacological Classes
Price Statistics
The NADAC for CALCIUM ACETATE 667 MG CAPSULE has been published 525 times since Sep 14, 2016, and over the history we have for it it has declined 52.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1697 per EA |
|---|---|
| All-time high | $0.5239 (Jul 15, 2020) |
| All-time low | $0.1369 (Nov 20, 2024) |
| 52-week high | $0.2096 |
| 52-week low | $0.1669 |
| Median price | $0.2173 |
| Average price | $0.2485 |
| Largest weekly change | +38.0% (May 13, 2020) |
| Weeks tracked | 525 |
| Tracking since | Sep 14, 2016 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Calcium Acetate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Blood Coagulation Factor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CALCIUM ACETATE 667 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CALCIUM ACETATE 667 MG CAPSULE, manufactured by Cipla USA Inc., is $0.1697 per EA (NDC 69097086283), effective Sep 30, 2026.
How has the price of CALCIUM ACETATE 667 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CALCIUM ACETATE 667 MG CAPSULE has declined 52.1%. It has been tracked across 525 weekly CMS publications since Sep 14, 2016.
What are the highest and lowest recorded NADAC prices for CALCIUM ACETATE 667 MG CAPSULE?
Since Sep 14, 2016, the NADAC for CALCIUM ACETATE 667 MG CAPSULE has ranged from a low of $0.1369 (Nov 20, 2024) to a high of $0.5239 (Jul 15, 2020), with a median of $0.2173 per EA.
Are there cheaper alternatives to CALCIUM ACETATE 667 MG CAPSULE?
8 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CALCIUM ACETATE 667 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures CALCIUM ACETATE 667 MG CAPSULE?
CALCIUM ACETATE 667 MG CAPSULE (NDC 69097086283) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.